



Leveraging EHR Capabilities to Support ORZEYFUL[®] (oveporexton) for the Treatment of Narcolepsy in Clinical Workflows

How Epic[®] capabilities can support prescribing workflows and medication visibility for ORZEYFUL

EHR=electronic health record.

INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





About This Guide

The purpose of this guide is to help healthcare providers order ORZEYFUL® (oveporexton), a treatment for narcolepsy type 1, and include it in prescribing workflow capabilities.

A provider may determine that a patient is appropriate for ORZEYFUL after reviewing diagnostic studies such as PSG and MSLT.

~~Information listed in this resource is based on the most recent version of Epic®; functions and features may change as new software versions are released.~~ This resource serves as summary information only and should not replace detailed instructions provided to you by your internal or external EHR support resources. It does not constitute medical advice, as treatment decisions should be based on independent medical judgment and individualized to patient needs.

Although the instructions have been tested on this EHR system, they are not guaranteed to work for all available software versions. Screen images shown represent hypothetical screens in Epic, and all examples are for discussion purposes only.

Takeda makes no claims or warranties about the applicability or appropriateness of this information, nor has this guide been endorsed by Epic.

The user is solely responsible for implementation, testing, and monitoring to ensure proper orientation in the EHR system.


Important Compliance Considerations for Scheduled Medications

Orzeyful is approved as a Schedule [IV/V, update when available] medication for the treatment of NT1. As a controlled substance, it requires standard medication build processes plus controlled substance-specific configuration to ensure compliance with federal (DEA), state, and organizational prescribing requirements.



The medication should be fully configured in the EHR drug file, including:

- Generic and brand name
- Strength, dosage form, and route
- Package descriptions aligned to NDC
- RxNorm and drug database linkages
- At least one active NDC to support e-prescribing
- DEA schedule classification
- EPCS requirements, including two-factor authentication, digital signature, and identity-proofed prescriber credentials



IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Discontinuation of ORZEYFUL: Discontinuation effects of oveporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





Table of Contents

About This Guide	2
Why This Matters.....	3
ORZEYFUL® (oveporexton) SmartSet	4
Adding a SmartGroup for Medications.....	4
Adding a SmartGroup to a SmartSet.....	6
OurPractice Advisory (OPA)	7
Creating an OPA Rule	7
Creating an OPA Base Record.....	8
Preferences	10
Sharing Patient Education Through the Patient Chart and MyChart Patient Portal	11
Information to Share with the EHR Team.....	11
Clinical Team Content Access and Use.....	12

Why This Matters

~~Narcolepsy type 1 (NT1)~~ is a chronic neurological disorder caused by a loss of orexin in the brain, a critical neurotransmitter that regulates the sleep-wake cycle.¹ Impaired orexin signaling can lead to excessive daytime sleepiness, cataplexy, and other symptoms that diminish patients' quality of life.^{1,2} Even with comprehensive management strategies, many patients continue to experience the burden of these symptoms.^{1,3}

As new treatment options become available, health systems need to ensure their clinical and EHR workflows are ready to support them. Updating workflow elements like order sets, preference lists, and documentation templates helps ensure consistent, accurate prescribing and reduces the need for manual workarounds at the point of care.

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 5\%$ and greater than placebo) reported in Phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).

Orzeyful[®]
oveporexton tablets(x)



ORZEYFUL® (oveporexton) SmartSet

SmartSets are a set of orderable and actionable items that include orderable items. SmartSets include SmartGroups, which can be used in multiple SmartSets for consistency across an organization. A SmartGroup organizes specific and related clinical items typically used together (eg, orders, medications) so that they can be easily managed and reused across the EHR. Once created, SmartGroups can be embedded into multiple different SmartSets or Order Sets to enable standard and consistent care without requiring the prescriber to search for what they need.

While a SmartGroup is a set of orders, a SmartSet encompasses all necessary components for a specific diagnosis, procedure, or patient encounter in a single screen – including SmartGroups and documentation tools.

The following steps provide an overview of the processes for adding medications, and patient education to SmartGroups.

Adding a SmartGroup for Medications

Adding medications to a SmartGroup supports consistent and efficient ordering at the point of care and during follow-up visits to reduce variation and reinforce alignment with established treatment pathways.

The screenshot shows a user interface for a SmartSet. It has a left-hand navigation menu with sections: Orders, Configuration, Medications, and Follow-Up. Under 'Medications', there are two entries: 'ORZEYFUL (oveporexton) 1 mg BID' and 'ORZEYFUL (oveporexton) 4 mg BID', each with a link to 'Order details'. Under 'Follow-Up', there is a 'Follow-up' section with a checkbox for '[4 weeks]' and a link to 'Follow-up summary'.

Example of a SmartSet for Orzeyful

IMPORTANT SAFETY INFORMATION (cont.)

DRUG INTERACTIONS

- Concomitant use with strong or moderate CYP3A inhibitors increases oveporexton exposures.
- Concomitant use of strong and moderate CYP3A inducers can increase oveporexton metabolism and therefore can decrease plasma levels of oveporexton.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





1. Search for and select **SmartGroups** [OSQ].
2. In the **Launching SmartGroup** window, select **+ Create a New Record**.
3. Enter an appropriate **Name** for the SmartGroup; for example, use **Medications** and select **Continue**.
4. To add orders to the new SmartGroup, select **Continue**, then select **Accept**.
5. Select **Add Item** from the toolbar.
6. In **Select Item Type**, use the dropdown to select the appropriate **Item Type**; for example, choose **Ambulatory Order**.
7. Search for the appropriate **Order** to add; for example, use ORZEYFUL, then select **Accept**.
8. Once the ORZEYFUL Order has been added, set appropriate details; for example, **Record name**, **Display name**, **Dose**, **Route**, and **Frequency**. Include specialty pharmacy routing details then select **Accept**.
 - a. Incorporating specialty pharmacy routing details may happen by adding an order comment and/or including routing instructions for [Accredo] Specialty Pharmacy.. **Creating a New SmartSet**

With a new SmartSet, both new and existing SmartGroups can be included, supporting efficiency by leveraging existing, validated content while maintaining consistency across workflows.

1. Search for and select **SmartSet** [PRL].
2. In the **Launching SmartSet** Editor window, select **+ Create a New Record**.
3. Enter the appropriate **Name** for the SmartSet; for example, use ORZEYFUL SmartSet. Select **Continue**.
4. To add SmartGroups to the new SmartSet, select **Accept**.
5. Under **SmartSet Type**, select **General**, and then select **Accept**.
6. The SmartSet Display Name defaults to the SmartSet record name. Change the Display Name as appropriate.

IMPORTANT SAFETY INFORMATION (cont.)

PREGNANCY AND LACTATION

- 1.1 There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call [1-800-XXX-XXXX].
 - There are no available data on the use of ORZEYFUL during pregnancy. There are no data available on the presence of oreporexton in human milk. Animal studies indicate that oreporexton was present in the milk of lactating rats.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).

Orzeyful[®]
oveporexton tablets(x)



Adding a SmartGroup to a SmartSet

After the SmartGroup is created, add it to the appropriate section within the SmartSet. In this example, we add a section in which to put our SmartGroup.

1. From the toolbar, select **+ Add Section**.
2. In the Section Configuration, enter a **Name**, such as **Medications**. Select appropriate options and restrictions per organizational standards. Select **Accept**.
3. Once the Section is created, select **+ Add SmartGroup**.
4. When all appropriate SmartGroups have been added to this SmartSet, select **Test Release** to test the SmartSet.
5. Once testing is complete, select **Release** for use by all users in the organization.

IMPORTANT SAFETY INFORMATION (cont.)

DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains the active ingredient oveporexton. (Controlled substance schedule to be determined after review by the Drug Enforcement Administration.)

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).

Orzeyful[®]
oveporexton tablets(x)



OurPractice Advisory (OPA)

An OPA is an EHR notification triggered when a patient meets predefined criteria. OPAs are designed to prompt consideration of a specific action (eg ordering tests, evaluating/reevaluating treatment, sending a referral, or scheduling follow-up care), and are delivered either as a pop-up alert in real time or as a message sent to a predefined pool or users In-basket.

Health systems determine the OPA content, display options, and intended clinical action in alignment with organizational goals, communication protocols, and system capabilities. Some benefits of using OPAs include:

- Supporting healthcare providers at the point of care with links to relevant clinical information
- Prompting appropriate actions or orders based on treatment protocols
- Improving consistency and standardization of care

Most organizations have an established process for submitting an OPA request to the EHR IT team. While example language may be included in technical configuration steps, healthcare providers and appropriate health system administrations should determine the final OPA message and intended action.

Example of an OPA highlighting the need for a specialty pharmacy to dispense ORZEYFUL

The following steps provide an overview of the processes for creating an OPA for routing an ORZEYFUL order through [Accredo] Specialty Pharmacy.

Creating an OPA Rule

1. Search for and select **OurPractice Advisory** and then **Rule Editor**.

INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





2. Create a **New Rule**.
 - a. **Context:** Patient OurPractice Advisory
 - b. **Name:** Name according to the health system's naming conventions; for example, ORZEYFUL® (oveporexton) Specialty Pharmacy
3. Select **Property**:
 - a. **Medications:** List desired medications to be involved; for example, ORZEYFUL
 - b. **Search Related Encounter?** No
 - c. **Order Status:** Pending
 - d. **Include/Exclude Order Status:** IncludeCreating OPA Criteria
4. Search for and select **OurPractice Advisory**.
5. Select **Create New Record**.
 - a. **Name:** ORZEYFUL® (oveporexton) Order
 - b. **Record Type:** Criteria
 - c. Select **Continue** and then select **Accept**.
6. Add a **Criteria Type** of **Rule** and **Medications (Include)**.
7. In **Medications (Include)** add required medications; for example, ORZEYFUL.
8. In **Rule**, add applicable **Rule** to find patients with a previously unsigned medication order.
9. Select **Release** and **Save**.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).



Creating an OPA Base Record

1. Search for and select **OurPractice Advisory**.
2. Select **Create New Record**.
 - a. **Name:** ORZEYFUL specialty pharmacy
 - b. **Record Type:** Base
 - c. Select **Continue**.
3. In **Display**, add applicable details for the provider; for example:
 - a. **Display to user?** Yes
 - b. **Unformatted Display Text:** Specialty pharmacy required
 - c. **Formatted Display Text:** ORZEYFUL requires prescription through [Accredo] Specialty Pharmacy
 - d. **Importance Level:** Important
4. In **Criteria**, add the appropriate inclusion and exclusion criteria.
5. In the **Restrictions** section, add applicable restrictions; for example, restrict by department specialty, such as Neurology. Provider-type restriction examples include physician, physician assistant, and nurse practitioner.
6. In the **Triggers** section, choose the appropriate Trigger, such as **Sign Orders**.
7. In the **Actions** section, choose appropriate Actions to take place.
8. In the **Active Guidelines URL** and **Active Guidelines Caption**, add appropriate URL to specialty pharmacy information; for example, ORZEYFUL Specialty Pharmacy List.
9. The **Acknowledge Reasons** section can be used as a method to gather additional data and allow the provider to dismiss the warning from appearing once acknowledged. Acknowledge Reasons may include:
 - a. Specialty pharmacy already selected
 - b. Order updated
 - c. Not applicable for this patient
10. Add **Default Lockout time:** 2 hours or as appropriate to organization standards.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Discontinuation of ORZEYFUL: Discontinuation effects of opeporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).

Orzeyful[®]
oveporexton tablets(x)



Preferences

Within the Preference List, providers can save frequently used medications, labs, procedures, and other orders as **My Favorites**, eliminating the need to re-enter the same information. In addition to the order name, favorites can include specific details like dosage, frequency, and quantity. A favorite can be saved in the healthcare provider's personal library or shared with other users within a practice or health system.

Benefits of saving a medication as a favorite include:

- Streamlining the prescribing process
- Ensuring accuracy and consistency

Individual favorites appear within a personal **Preference List** and are typically managed by the individual clinical user. Shared favorites may appear within the Facility List and are typically managed by the health system EHR team.

Adding ORZEYFUL® (oveporexton) to a Preference List

1. Search for ORZEYFUL in the **Database** tab.
2. **Select** the desired strength and formulation to display order details. If applicable, this process can be repeated for multiple dosage strengths.
3. Enter or confirm the order details such as **Dose, Route, Frequency, and Patient SIG.**
4. Select **Accept** to order the prescription.
5. Select the star icon ★ to the right of the prescription to save as a **Favorite**.
6. To select a medication that has been saved as a Favorite, open the **Preference List** and select the medication of choice.

The screenshot shows a web application window titled "Order Search". At the top, there is a search bar containing "ORZEYFUL (oveporexton)" and a magnifying glass icon. Below the search bar are tabs for "Browse", "Preference List" (which is selected), "Facility List", and "Database". Under the "Preference List" tab, there is a "Panels" section with "(No results found)" and a search box "Search panels by user". Below that is a "Medications" section with an expandable arrow. It contains a table with the following data:

Name	Dose	Frequency	Drug Type	Formulary
ORZEYFUL (oveporexton)	1 mg	BID	Brand Rx	
ORZEYFUL (oveporexton)	1 mg	BID	Brand Rx	

Example of a Preference List search with details for ORZEYFUL

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) reported in Phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





Sharing Patient Education Through the Patient Chart and MyChart Patient Portal

In order to share patient education in the After Visit Summary® (AVS) in MyChart®, the content must first be configured by the EHR Team as an orderable. As part of the configuration, educational content can be mapped to diagnoses, medications, procedures, SmartSets, and SmartGroups.

When submitting a request to include variable patient education resources as Clinical Resources, consider including the following information along with the document and/or a link to the resource:

Information to Share with the EHR Team

Information	Details to include
Name or Title of Resource	For example, ORZEYFUL® (oveporexton) Dosing and Administration guide
Contents to Share	Links to resources to include with preferred format indicated (eg PDF, web-based content)
Configuration Request	Consider requests such as: <ul style="list-style-type: none"> • Make available within Patient Education activity, Order Composer • Enable inclusion in the AVS • Configure availability in MyChart for patient access • Associate with relevant SmartSets, SmartGroups, order workflows
Clinical Context, Trigger	Define when information should be available: <ul style="list-style-type: none"> • Diagnosis-based (eg, Narcolepsy type 1) • Medication-based (eg, ORZEYFUL) • Manual selection • Included in specific SmartSets
Define the Audience for the Document	<ul style="list-style-type: none"> • Patients interested in learning more about treatment with ORZEYFUL
External Resources	<ul style="list-style-type: none"> • Approved external website link

IMPORTANT SAFETY INFORMATION (cont.)

DRUG INTERACTIONS

- Concomitant use with strong or moderate CYP3A inhibitors increases oveporexton exposures.
- Concomitant use of strong and moderate CYP3A inducers can increase oveporexton metabolism and therefore can decrease plasma levels of oveporexton.

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).





Clinical Team Content Access and Use

Patient Education Content	Clinician Workflow & Patient Delivery
ORZEYFUL® (oveporexton) Patient Education	<ul style="list-style-type: none"> • Accessed via the Patient Education Activity or Chart Search • Accessed via SmartSets, SmartGroups, if configured as education orders • Used by clinicians as a supporting resource during patient discussions • Selected content can be included in the AVS • Shared with patients via MyChart or printed materials
Optional External Patient Resources (Enabling Patient Access to External Information)	<ul style="list-style-type: none"> • ORZEYFUL patient website link [add hyperlink when available]

IMPORTANT SAFETY INFORMATION (cont.)

PREGNANCY AND LACTATION

- 1.1 There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call [1-800-XXX-XXXX].
- There are no available data on the use of ORZEYFUL during pregnancy. There are no data available on the presence of oveporexton in human milk. Animal studies indicate that oveporexton was present in the milk of lactating rats.

DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains the active ingredient oveporexton. (Controlled substance schedule to be determined after review by the Drug Enforcement Administration.)

Please see additional Important Safety Information on page 12 and click for [full Prescribing Information](#).

Orzeyful[®]
oveporexton tablets(x)



INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

WARNINGS AND PRECAUTIONS

Discontinuation of ORZEYFUL: Discontinuation effects of ovesporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 5\%$ and greater than placebo) reported in Phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

DRUG INTERACTIONS

- Concomitant use with strong or moderate CYP3A inhibitors increases ovesporexton exposures.
- Concomitant use of strong and moderate CYP3A inducers can increase ovesporexton metabolism and therefore can decrease plasma levels of ovesporexton.

PREGNANCY AND LACTATION

- 1.1 There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call [1-800-XXX-XXXX].
- There are no available data on the use of ORZEYFUL during pregnancy. There are no data available on the presence of ovesporexton in human milk. Animal studies indicate that ovesporexton was present in the milk of lactating rats.

DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains the active ingredient ovesporexton. (Controlled substance schedule to be determined after review by the Drug Enforcement Administration.)



ABOUT THIS GUIDE

WHY THIS MATTERS

SMARTSET

OPA

PREFERENCES

PATIENT EDUCATION

References: **1.** Krahn LE, Zee PE, Thorpy MJ. Current understanding of narcolepsy 1 and its comorbidities: what clinicians need to know. *Adv Ther.* 2022;39(1):221-243. <https://doi.org/10.1007/s12325-021-01992-4> Accessed April 27, 2026. **2.** Scammell TE. Narcolepsy. *N Engl J Med.* 2015;373(27):2654-2662. <https://doi.org/10.1056/NEJMra1500587> Accessed April 27, 2026. **3.** Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. *J Clin Sleep Med.* 2017;13(3):419-425. <https://doi.org/10.5664/jcsm.6494> Accessed April 27, 2026.

©2026 Takeda Pharmaceuticals U.S.A., Inc.
500 Kendall Street, Cambridge, MA 02142.
1-877-TAKEDA-7 (1-877-825-3327).
All rights reserved.

TAKEDA and the  are registered trademarks of Takeda Pharmaceutical Company Limited.

Epic is a registered trademark of Epic Systems Corporation.

All other trademarks are the property of their respective owners.

US-OVE-0373 05/26

Orzeyful[®]
oveporexton tablets(x)